Drug Trial Radar · NCT05896670
Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease
Last checked: Nov 19, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
122
Actual
Start
Nov 29, 2023
Primary completion
Mar 27, 2024
Study completion Mar 27, 2024
Sponsor
- Lead sponsor
- OculisIndustry
- Sponsor type
- Industry
- Collaborators
- ORA, Inc.
- First posted
- Jun 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic solution is more effective than vehicle in treating signs of dry eye disease.
Conditions
- Dry Eye Disease
Interventions
licaminlimabDrug
ophthalmic solution 60 mg/mL Subjects will be randomized to receive licaminlimab eye drops three times daily (TID) for 6 weeks.
vehicle of OCS-02Other
inert ophthalmic solution vehicle of OCS-02 Subjects will be randomized to receive vehicle eye drops three times daily (TID) for 6 weeks.
Artificial tearsOther
Subjects who quality after an initial screening were entered into a run-in phase where they received artificial tears to use three times daily (TID) for approximately 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of licaminlimab in subjects with signs of dry eye diseaseTime frame: Baseline to Day 43
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Oculis Investigative Site
Newport Beach, California
Oculis Investigative Site
Colorado Springs, Colorado
Oculis Investigative Site
Shelby, North Carolina
Oculis Investigative Site
Erie, Pennsylvania
Oculis Investigative Site
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.